Top-Rated StocksTop-RatedNASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis $11.85 +0.20 (+1.72%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$11.63 -0.22 (-1.86%) As of 09/15/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amylyx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$11.42▼$12.1250-Day Range$6.98▼$11.8552-Week Range$2.59▼$12.25Volume1.93 million shsAverage Volume1.83 million shsMarket Capitalization$1.06 billionP/E RatioN/ADividend YieldN/APrice Target$13.25Consensus RatingBuy Company Overview Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options. The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S. Food and Drug Administration approval in 2022 for the treatment of amyotrophic lateral sclerosis (ALS). Amylyx has also filed for regulatory approval of AMX0035 (known as Albrioza) in the European Union and continues to explore its potential utility in other neurodegenerative disorders. In addition to ALS, the Amylyx pipeline includes early-stage programs investigating therapies for Alzheimer’s disease and GM1 gangliosidosis, reflecting the company’s broader commitment to addressing central nervous system pathologies. Amylyx operates primarily in North America and is advancing its global development and commercialization capabilities through strategic collaborations and regulatory engagements. Under the leadership of Chief Executive Officer John H. Johnson III, the company continues to expand clinical development efforts and strengthen its manufacturing and distribution networks. Amylyx’s multidisciplinary team of scientists, clinicians and regulatory experts works to translate preclinical discoveries into potential therapies for patients facing critical neurological challenges.AI Generated. May Contain Errors. Read More Amylyx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreAMLX MarketRank™: Amylyx Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 654th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingBuy Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialAmylyx Pharmaceuticals has a consensus price target of $13.25, representing about 11.8% upside from its current price of $11.85.Amount of Analyst CoverageAmylyx Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amylyx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($2.20) to ($1.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -4.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 4.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amylyx Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.64% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently increased by 13.19%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.64% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently increased by 13.19%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment1.03 News SentimentAmylyx Pharmaceuticals has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Amylyx Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest9 people have searched for AMLX on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.30% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amylyx Pharmaceuticals' insider trading history. Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMLX Stock News HeadlinesWill Amylyx Pharmaceuticals’ (AMLX) $175 Million Capital Raise Reshape Its Pipeline Ambitions?September 13 at 11:32 AM | finance.yahoo.comAmylyx Pharmaceuticals shares fall after $175 million follow-on offeringSeptember 10, 2025 | au.investing.comOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next ChatGPT models, and Porter Stansberry says the real opportunity isn’t in flashy AI apps but in the infrastructure behind them — data centers, fiber networks, energy, and more — with eight companies best positioned to profit from this massive shift. | Porter & Company (Ad)Amylyx Pharmaceuticals Stock Slips After Discounted $175M Share SaleSeptember 10, 2025 | msn.comAmylyx Pharmaceuticals prices $175M public offeringSeptember 10, 2025 | msn.comAmylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common StockSeptember 9, 2025 | businesswire.comAmylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 8, 2025 | seekingalpha.comAmylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi's Biopharma Back to School Conference - SlideshowSeptember 2, 2025 | seekingalpha.comSee More Headlines AMLX Stock Analysis - Frequently Asked Questions How have AMLX shares performed this year? Amylyx Pharmaceuticals' stock was trading at $3.78 on January 1st, 2025. Since then, AMLX shares have increased by 213.5% and is now trading at $11.85. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) released its quarterly earnings results on Thursday, August, 7th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.02. Read the conference call transcript. When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Top institutional shareholders of Amylyx Pharmaceuticals include Adage Capital Partners GP L.L.C. (9.87%), Perceptive Advisors LLC (8.86%), Saturn V Capital Management LP (3.66%) and 683 Capital Management LLC (2.42%). Insiders that own company stock include Morningside Venture Investment, Joshua B Cohen, Justin B Klee, George M Milne Jr, James M Frates, Patrick D Yeramian, Camille L Bedrosian, Gina Mazzariello, Bernhardt G Zeiher and Daphne Quimi. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amylyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/07/2025Today9/15/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMLX CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Price Target for Amylyx Pharmaceuticals$13.25 High Price Target$25.00 Low Price Target$8.00 Potential Upside/Downside+11.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$301.74 million Net MarginsN/A Pretax Margin-345.81% Return on Equity-82.48% Return on Assets-70.15% Debt Debt-to-Equity RatioN/A Current Ratio8.72 Quick Ratio8.72 Sales & Book Value Annual Sales$87.37 million Price / Sales12.10 Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book4.94Miscellaneous Outstanding Shares89,170,000Free Float78,199,000Market Cap$1.06 billion OptionableOptionable Beta-0.45 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:AMLX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.